Antiepileptic Drugs Market By Drug (First Generation, Second Generation, Third Generation) , By Route of Administration (Oral, Intravenous) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores) : Global Opportunity Analysis and Industry Forecast, 2024-2033
The antiepileptic drugs market was valued at $16.8 billion in 2023, and is projected to reach $27.5 billion by 2033, growing at a CAGR of 5.1% from 2024 to 2033.
Antiepileptic drugs, also known as anticonvulsants, are medications formulated to prevent or reduce the frequency and severity of seizures in individuals with epilepsy. Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures resulting from abnormal electrical activity in the brain. Antiepileptic drugs work by stabilizing nerve cell membranes and modulating neurotransmitter activity to prevent this abnormal firing, helping to control seizure episodes.
The growth of the global antiepileptic drugs market is driven by alarming increase in prevalence of epilepsy and other neurological conditions. According to a study published by the World Health Organization in February 2024, approximately 50 million individuals suffer from epilepsy globally, thus making it the most common neurological disorders. In addition, improved diagnostic methods and growing awareness of epilepsy in healthcare systems contribute to earlier diagnoses and the expansion of the patient base for antiepileptic drugs. Moreover, surge in geriatric population notably contributes toward the growth of the global market. This is majorly attributed to the fact that aged individuals are more susceptible to falls, which can lead to head trauma. Traumatic brain injuries are a significant cause of seizures. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050. Furthermore, significant government and healthcare support for epilepsy treatment acts as the key driving force of the global market. However, side effects associated with antiepileptic drugs such as drowsiness, dizziness, cognitive impairment, mood changes, and, in some cases, serious allergic reactions hamper the market growth. Moreover, availability of alternative non-pharmacological treatments, such as surgical interventions, ketogenic diets, and neuromodulation therapies restrains the market growth. On the contrary, ongoing R&D have led to the formulation of novel antiepileptic drugs with fewer side effects and improved efficacy and Innovations in drug delivery methods like extended release formulations are expected to offer lucrative opportunities for the expansion of the global market during the forecast period.
The global antiepileptic drugs industry is segmented into drug, route of administration, distribution channel, and region. By drug, the market is classified into first generation, second generation, third generation. On the basis of route of administration, it is divided into oral and intravenous. Depending on distribution channel, it is segregated into hospital pharmacies, retail pharmacies, online pharmacies, and drug stores. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By drug, the second-generation segment held the highest market share in 2023.
On the basis of route of administration, the oral segment garnered the largest share in 2023.
Depending on distribution channel, the hospital segment was the major shareholder in 2023.
Region wise, North America held the highest market share in 2023, and is poised to maintain its leadership from 2024 to 2033.
Competition Analysis
Competitive analysis and profiles of the major players in the global antiepileptic drugs market include Johnson & Johnson, Merck KGaA, Eisai Co., Ltd., AstraZeneca, Novartis AG, Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Pfizer Inc., GlaxoSmithKline Plc, and Sanofi. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.
Additional benefits you will get with this purchase are:
By Drug
Antiepileptic drugs, also known as anticonvulsants, are medications formulated to prevent or reduce the frequency and severity of seizures in individuals with epilepsy. Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures resulting from abnormal electrical activity in the brain. Antiepileptic drugs work by stabilizing nerve cell membranes and modulating neurotransmitter activity to prevent this abnormal firing, helping to control seizure episodes.
The growth of the global antiepileptic drugs market is driven by alarming increase in prevalence of epilepsy and other neurological conditions. According to a study published by the World Health Organization in February 2024, approximately 50 million individuals suffer from epilepsy globally, thus making it the most common neurological disorders. In addition, improved diagnostic methods and growing awareness of epilepsy in healthcare systems contribute to earlier diagnoses and the expansion of the patient base for antiepileptic drugs. Moreover, surge in geriatric population notably contributes toward the growth of the global market. This is majorly attributed to the fact that aged individuals are more susceptible to falls, which can lead to head trauma. Traumatic brain injuries are a significant cause of seizures. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050. Furthermore, significant government and healthcare support for epilepsy treatment acts as the key driving force of the global market. However, side effects associated with antiepileptic drugs such as drowsiness, dizziness, cognitive impairment, mood changes, and, in some cases, serious allergic reactions hamper the market growth. Moreover, availability of alternative non-pharmacological treatments, such as surgical interventions, ketogenic diets, and neuromodulation therapies restrains the market growth. On the contrary, ongoing R&D have led to the formulation of novel antiepileptic drugs with fewer side effects and improved efficacy and Innovations in drug delivery methods like extended release formulations are expected to offer lucrative opportunities for the expansion of the global market during the forecast period.
The global antiepileptic drugs industry is segmented into drug, route of administration, distribution channel, and region. By drug, the market is classified into first generation, second generation, third generation. On the basis of route of administration, it is divided into oral and intravenous. Depending on distribution channel, it is segregated into hospital pharmacies, retail pharmacies, online pharmacies, and drug stores. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By drug, the second-generation segment held the highest market share in 2023.
On the basis of route of administration, the oral segment garnered the largest share in 2023.
Depending on distribution channel, the hospital segment was the major shareholder in 2023.
Region wise, North America held the highest market share in 2023, and is poised to maintain its leadership from 2024 to 2033.
Competition Analysis
Competitive analysis and profiles of the major players in the global antiepileptic drugs market include Johnson & Johnson, Merck KGaA, Eisai Co., Ltd., AstraZeneca, Novartis AG, Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Pfizer Inc., GlaxoSmithKline Plc, and Sanofi. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Average Selling Price Analysis / Price Point Analysis
- Expanded list for Company Profiles
- Historic market data
By Drug
- First Generation
- Second Generation
- Third Generation
- Oral
- Intravenous
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Johnson & Johnson
- Merck KGaA
- Eisai Co., Ltd.
- AstraZeneca
- Novartis AG
- Abbott Laboratories
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- GlaxoSmithKline Plc
- Sanofi
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: ANTIEPILEPTIC DRUGS MARKET, BY DRUG
4.1. Market Overview
4.1.1 Market Size and Forecast, By Drug
4.2. First Generation
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Second Generation
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Third Generation
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
CHAPTER 5: ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Route Of Administration
5.2. Oral
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Intravenous
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Market Overview
6.1.1 Market Size and Forecast, By Distribution Channel
6.2. Hospital Pharmacies
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Retail Pharmacies
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Online Pharmacies
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
6.5. Drug Stores
6.5.1. Key Market Trends, Growth Factors and Opportunities
6.5.2. Market Size and Forecast, By Region
6.5.3. Market Share Analysis, By Country
CHAPTER 7: ANTIEPILEPTIC DRUGS MARKET, BY REGION
7.1. Market Overview
7.1.1 Market Size and Forecast, By Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Drug
7.2.3. Market Size and Forecast, By Route Of Administration
7.2.4. Market Size and Forecast, By Distribution Channel
7.2.5. Market Size and Forecast, By Country
7.2.6. U.S. Antiepileptic Drugs Market
7.2.6.1. Market Size and Forecast, By Drug
7.2.6.2. Market Size and Forecast, By Route Of Administration
7.2.6.3. Market Size and Forecast, By Distribution Channel
7.2.7. Canada Antiepileptic Drugs Market
7.2.7.1. Market Size and Forecast, By Drug
7.2.7.2. Market Size and Forecast, By Route Of Administration
7.2.7.3. Market Size and Forecast, By Distribution Channel
7.2.8. Mexico Antiepileptic Drugs Market
7.2.8.1. Market Size and Forecast, By Drug
7.2.8.2. Market Size and Forecast, By Route Of Administration
7.2.8.3. Market Size and Forecast, By Distribution Channel
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, By Drug
7.3.3. Market Size and Forecast, By Route Of Administration
7.3.4. Market Size and Forecast, By Distribution Channel
7.3.5. Market Size and Forecast, By Country
7.3.6. Germany Antiepileptic Drugs Market
7.3.6.1. Market Size and Forecast, By Drug
7.3.6.2. Market Size and Forecast, By Route Of Administration
7.3.6.3. Market Size and Forecast, By Distribution Channel
7.3.7. France Antiepileptic Drugs Market
7.3.7.1. Market Size and Forecast, By Drug
7.3.7.2. Market Size and Forecast, By Route Of Administration
7.3.7.3. Market Size and Forecast, By Distribution Channel
7.3.8. UK Antiepileptic Drugs Market
7.3.8.1. Market Size and Forecast, By Drug
7.3.8.2. Market Size and Forecast, By Route Of Administration
7.3.8.3. Market Size and Forecast, By Distribution Channel
7.3.9. Italy Antiepileptic Drugs Market
7.3.9.1. Market Size and Forecast, By Drug
7.3.9.2. Market Size and Forecast, By Route Of Administration
7.3.9.3. Market Size and Forecast, By Distribution Channel
7.3.10. Spain Antiepileptic Drugs Market
7.3.10.1. Market Size and Forecast, By Drug
7.3.10.2. Market Size and Forecast, By Route Of Administration
7.3.10.3. Market Size and Forecast, By Distribution Channel
7.3.11. Rest Of Europe Antiepileptic Drugs Market
7.3.11.1. Market Size and Forecast, By Drug
7.3.11.2. Market Size and Forecast, By Route Of Administration
7.3.11.3. Market Size and Forecast, By Distribution Channel
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, By Drug
7.4.3. Market Size and Forecast, By Route Of Administration
7.4.4. Market Size and Forecast, By Distribution Channel
7.4.5. Market Size and Forecast, By Country
7.4.6. Japan Antiepileptic Drugs Market
7.4.6.1. Market Size and Forecast, By Drug
7.4.6.2. Market Size and Forecast, By Route Of Administration
7.4.6.3. Market Size and Forecast, By Distribution Channel
7.4.7. China Antiepileptic Drugs Market
7.4.7.1. Market Size and Forecast, By Drug
7.4.7.2. Market Size and Forecast, By Route Of Administration
7.4.7.3. Market Size and Forecast, By Distribution Channel
7.4.8. Australia Antiepileptic Drugs Market
7.4.8.1. Market Size and Forecast, By Drug
7.4.8.2. Market Size and Forecast, By Route Of Administration
7.4.8.3. Market Size and Forecast, By Distribution Channel
7.4.9. India Antiepileptic Drugs Market
7.4.9.1. Market Size and Forecast, By Drug
7.4.9.2. Market Size and Forecast, By Route Of Administration
7.4.9.3. Market Size and Forecast, By Distribution Channel
7.4.10. South Korea Antiepileptic Drugs Market
7.4.10.1. Market Size and Forecast, By Drug
7.4.10.2. Market Size and Forecast, By Route Of Administration
7.4.10.3. Market Size and Forecast, By Distribution Channel
7.4.11. Rest of Asia-Pacific Antiepileptic Drugs Market
7.4.11.1. Market Size and Forecast, By Drug
7.4.11.2. Market Size and Forecast, By Route Of Administration
7.4.11.3. Market Size and Forecast, By Distribution Channel
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, By Drug
7.5.3. Market Size and Forecast, By Route Of Administration
7.5.4. Market Size and Forecast, By Distribution Channel
7.5.5. Market Size and Forecast, By Country
7.5.6. Brazil Antiepileptic Drugs Market
7.5.6.1. Market Size and Forecast, By Drug
7.5.6.2. Market Size and Forecast, By Route Of Administration
7.5.6.3. Market Size and Forecast, By Distribution Channel
7.5.7. Saudi Arabia Antiepileptic Drugs Market
7.5.7.1. Market Size and Forecast, By Drug
7.5.7.2. Market Size and Forecast, By Route Of Administration
7.5.7.3. Market Size and Forecast, By Distribution Channel
7.5.8. South Africa Antiepileptic Drugs Market
7.5.8.1. Market Size and Forecast, By Drug
7.5.8.2. Market Size and Forecast, By Route Of Administration
7.5.8.3. Market Size and Forecast, By Distribution Channel
7.5.9. Rest of LAMEA Antiepileptic Drugs Market
7.5.9.1. Market Size and Forecast, By Drug
7.5.9.2. Market Size and Forecast, By Route Of Administration
7.5.9.3. Market Size and Forecast, By Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping Of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Johnson And Johnson
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Merck KGaA
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Eisai Co., Ltd.
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. AstraZeneca
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. Novartis AG
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. Abbott Laboratories
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. Teva Pharmaceutical Industries Ltd.
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. Pfizer Inc.
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. GlaxoSmithKline Plc
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. Sanofi
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: ANTIEPILEPTIC DRUGS MARKET, BY DRUG
4.1. Market Overview
4.1.1 Market Size and Forecast, By Drug
4.2. First Generation
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Second Generation
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Third Generation
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
CHAPTER 5: ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Route Of Administration
5.2. Oral
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Intravenous
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Market Overview
6.1.1 Market Size and Forecast, By Distribution Channel
6.2. Hospital Pharmacies
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Retail Pharmacies
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Online Pharmacies
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
6.5. Drug Stores
6.5.1. Key Market Trends, Growth Factors and Opportunities
6.5.2. Market Size and Forecast, By Region
6.5.3. Market Share Analysis, By Country
CHAPTER 7: ANTIEPILEPTIC DRUGS MARKET, BY REGION
7.1. Market Overview
7.1.1 Market Size and Forecast, By Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Drug
7.2.3. Market Size and Forecast, By Route Of Administration
7.2.4. Market Size and Forecast, By Distribution Channel
7.2.5. Market Size and Forecast, By Country
7.2.6. U.S. Antiepileptic Drugs Market
7.2.6.1. Market Size and Forecast, By Drug
7.2.6.2. Market Size and Forecast, By Route Of Administration
7.2.6.3. Market Size and Forecast, By Distribution Channel
7.2.7. Canada Antiepileptic Drugs Market
7.2.7.1. Market Size and Forecast, By Drug
7.2.7.2. Market Size and Forecast, By Route Of Administration
7.2.7.3. Market Size and Forecast, By Distribution Channel
7.2.8. Mexico Antiepileptic Drugs Market
7.2.8.1. Market Size and Forecast, By Drug
7.2.8.2. Market Size and Forecast, By Route Of Administration
7.2.8.3. Market Size and Forecast, By Distribution Channel
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, By Drug
7.3.3. Market Size and Forecast, By Route Of Administration
7.3.4. Market Size and Forecast, By Distribution Channel
7.3.5. Market Size and Forecast, By Country
7.3.6. Germany Antiepileptic Drugs Market
7.3.6.1. Market Size and Forecast, By Drug
7.3.6.2. Market Size and Forecast, By Route Of Administration
7.3.6.3. Market Size and Forecast, By Distribution Channel
7.3.7. France Antiepileptic Drugs Market
7.3.7.1. Market Size and Forecast, By Drug
7.3.7.2. Market Size and Forecast, By Route Of Administration
7.3.7.3. Market Size and Forecast, By Distribution Channel
7.3.8. UK Antiepileptic Drugs Market
7.3.8.1. Market Size and Forecast, By Drug
7.3.8.2. Market Size and Forecast, By Route Of Administration
7.3.8.3. Market Size and Forecast, By Distribution Channel
7.3.9. Italy Antiepileptic Drugs Market
7.3.9.1. Market Size and Forecast, By Drug
7.3.9.2. Market Size and Forecast, By Route Of Administration
7.3.9.3. Market Size and Forecast, By Distribution Channel
7.3.10. Spain Antiepileptic Drugs Market
7.3.10.1. Market Size and Forecast, By Drug
7.3.10.2. Market Size and Forecast, By Route Of Administration
7.3.10.3. Market Size and Forecast, By Distribution Channel
7.3.11. Rest Of Europe Antiepileptic Drugs Market
7.3.11.1. Market Size and Forecast, By Drug
7.3.11.2. Market Size and Forecast, By Route Of Administration
7.3.11.3. Market Size and Forecast, By Distribution Channel
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, By Drug
7.4.3. Market Size and Forecast, By Route Of Administration
7.4.4. Market Size and Forecast, By Distribution Channel
7.4.5. Market Size and Forecast, By Country
7.4.6. Japan Antiepileptic Drugs Market
7.4.6.1. Market Size and Forecast, By Drug
7.4.6.2. Market Size and Forecast, By Route Of Administration
7.4.6.3. Market Size and Forecast, By Distribution Channel
7.4.7. China Antiepileptic Drugs Market
7.4.7.1. Market Size and Forecast, By Drug
7.4.7.2. Market Size and Forecast, By Route Of Administration
7.4.7.3. Market Size and Forecast, By Distribution Channel
7.4.8. Australia Antiepileptic Drugs Market
7.4.8.1. Market Size and Forecast, By Drug
7.4.8.2. Market Size and Forecast, By Route Of Administration
7.4.8.3. Market Size and Forecast, By Distribution Channel
7.4.9. India Antiepileptic Drugs Market
7.4.9.1. Market Size and Forecast, By Drug
7.4.9.2. Market Size and Forecast, By Route Of Administration
7.4.9.3. Market Size and Forecast, By Distribution Channel
7.4.10. South Korea Antiepileptic Drugs Market
7.4.10.1. Market Size and Forecast, By Drug
7.4.10.2. Market Size and Forecast, By Route Of Administration
7.4.10.3. Market Size and Forecast, By Distribution Channel
7.4.11. Rest of Asia-Pacific Antiepileptic Drugs Market
7.4.11.1. Market Size and Forecast, By Drug
7.4.11.2. Market Size and Forecast, By Route Of Administration
7.4.11.3. Market Size and Forecast, By Distribution Channel
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, By Drug
7.5.3. Market Size and Forecast, By Route Of Administration
7.5.4. Market Size and Forecast, By Distribution Channel
7.5.5. Market Size and Forecast, By Country
7.5.6. Brazil Antiepileptic Drugs Market
7.5.6.1. Market Size and Forecast, By Drug
7.5.6.2. Market Size and Forecast, By Route Of Administration
7.5.6.3. Market Size and Forecast, By Distribution Channel
7.5.7. Saudi Arabia Antiepileptic Drugs Market
7.5.7.1. Market Size and Forecast, By Drug
7.5.7.2. Market Size and Forecast, By Route Of Administration
7.5.7.3. Market Size and Forecast, By Distribution Channel
7.5.8. South Africa Antiepileptic Drugs Market
7.5.8.1. Market Size and Forecast, By Drug
7.5.8.2. Market Size and Forecast, By Route Of Administration
7.5.8.3. Market Size and Forecast, By Distribution Channel
7.5.9. Rest of LAMEA Antiepileptic Drugs Market
7.5.9.1. Market Size and Forecast, By Drug
7.5.9.2. Market Size and Forecast, By Route Of Administration
7.5.9.3. Market Size and Forecast, By Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping Of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Johnson And Johnson
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Merck KGaA
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Eisai Co., Ltd.
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. AstraZeneca
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. Novartis AG
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. Abbott Laboratories
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. Teva Pharmaceutical Industries Ltd.
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. Pfizer Inc.
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. GlaxoSmithKline Plc
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. Sanofi
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments
